Glioblastoma News and Research

RSS
Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Preclinical efficacy data of Sangamo's ZFN based human stem cell therapy for HIV published

Preclinical efficacy data of Sangamo's ZFN based human stem cell therapy for HIV published

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

Survey: 66% of patients with metastatic colorectal cancer are now tested for KRAS

Neuralstem announces completion of $10 million registered direct offering

Neuralstem announces completion of $10 million registered direct offering

Sirnaomics receives NIH SBIR grants to advance siRNA therapeutics for critical human diseases

Sirnaomics receives NIH SBIR grants to advance siRNA therapeutics for critical human diseases

IMUC signs exclusive licensing agreement with Targepeutics for acquisition of IL-13Ra2 receptor

IMUC signs exclusive licensing agreement with Targepeutics for acquisition of IL-13Ra2 receptor

Exelixis announces regaining of rights to develop and commercialize XL184

Exelixis announces regaining of rights to develop and commercialize XL184

First patient dosed in AR-42 Phase I/IIa clinical study at OSUCCC-James in adult patients with blood cancer

First patient dosed in AR-42 Phase I/IIa clinical study at OSUCCC-James in adult patients with blood cancer

Bayer, OncoMed collaborate to develop anti-cancer stem cell therapeutics to target Wnt signaling pathway

Bayer, OncoMed collaborate to develop anti-cancer stem cell therapeutics to target Wnt signaling pathway

OncoMed, Bayer Schering Pharma to develop and commercialize novel anti-cancer stem cell therapeutics

OncoMed, Bayer Schering Pharma to develop and commercialize novel anti-cancer stem cell therapeutics

FDA grants orphan drug designation for ICT-107

FDA grants orphan drug designation for ICT-107

Nativis awarded patents in Japan, China, India for drug signal technology

Nativis awarded patents in Japan, China, India for drug signal technology

NWBT announces release of new detailed report by Pharmaceuticals and Biotech Analyst

NWBT announces release of new detailed report by Pharmaceuticals and Biotech Analyst

Myriad Pharmaceuticals announces strategic initiatives to focus on oncology pipeline

Myriad Pharmaceuticals announces strategic initiatives to focus on oncology pipeline

FDA approves City of Hope's neural stem cell-based therapy study for recurrent high-grade gliomas

FDA approves City of Hope's neural stem cell-based therapy study for recurrent high-grade gliomas

Clinical data from two separate Phase 2a combination drug studies of Azixa presented at ASCO 2010

Clinical data from two separate Phase 2a combination drug studies of Azixa presented at ASCO 2010

Angiochem presents positive Phase 1/2 clinical data of ANG1005 for brain cancer at ASCO 2010

Angiochem presents positive Phase 1/2 clinical data of ANG1005 for brain cancer at ASCO 2010

CytRx granted U.S. Patent for bafetinib

CytRx granted U.S. Patent for bafetinib

PTC receives $5.4M SDD Award to support development of drugs that target Bmi-1

PTC receives $5.4M SDD Award to support development of drugs that target Bmi-1

Merck Serono reports long-term follow-up data of cilengitide Phase II study for recurrent glioblastoma

Merck Serono reports long-term follow-up data of cilengitide Phase II study for recurrent glioblastoma

Exelixis reports updated interim data from trials of XL765 small molecule inhibitor of PI3K and mTOR

Exelixis reports updated interim data from trials of XL765 small molecule inhibitor of PI3K and mTOR

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.